October 6 groundbreaking ceremony expands company’s presence in the U.S.
Asia
Europe, Middle East, Africa
North America
bioMérieux to Develop New Highly-Specific, Non-Invasive Test for Prostate Cancer, Reducing Unnecessary Biopsies
25 September, 2008
Prostate cancer is the most prevalent cancer in the United States and the 4th most common worldwide. The combination of a test for a new prostate cancer biomarker, Annexin 3, with the standard screening methods could potentially reduce the number of biopsies conducted by up to 75%, when compared with current screening methods alone.
bioMérieux Gains Critical Oncology and Theranostics Capabilities with the Acquisition of Molecular Diagnostics Company AviaraDx
11 September, 2008
bioMérieux, a world leader in the field of in vitro diagnostics has acquired the privately held AviaraDx, Inc., a molecular in vitro diagnostics company, based in San Diego, California (USA). AviaraDx’s diagnostic tests, based on their proprietary technologies, are used in the molecular classification of cancers and to assist oncologists in making critical therapeutic decisions. The company has built a molecular R&D lab and a small sales & marketing team, as well as a high complexity Clinical Laboratory Improvement Amendments (CLIA) certified service lab.
First-Half 2008 Financial Report
08 September, 2008
bioMérieux (Euronext: BIM), a global leader in the field of in vitro diagnostics, today released its interim financial report for the first six months of 2008.
Steve Harbin's Appointment
01 September, 2008
A world leader in the field of in vitro diagnostics, bioMérieux has appointed Steve Harbin as Corporate Vice President, Quality Management Systems, Health, Safety and Environment and Internal Control, effective July 15, 2008.
bioMérieux Delivers New Clean Room Range for Sterility Testing
01 September, 2008
pharma_media1_thumb15.jpg bioMérieux, a world leader in in vitro diagnostics, launches sterility media bottles in a new format, the Clean Room Range, for ultimate quality and ease of use in final product testing of sterile pharmaceutical compounds.
bioMérieux Receives FDA Clearance for Expanded Claims with VIDAS® C. difficile Toxin A&B, Enhancing Testing Solutions for Hospital Infection Control
06 August, 2008
VIDAS® offers the only fully automated test for C. difficile Toxin A&B.
bioMérieux to Reveal the Latest Food Safety Technology at the International Association of Food Protection Annual Meeting
30 July, 2008
Seventh Annual Symposium to cover food-borne outbreaks including Salmonella and E. coli O157:H7.
bioMérieux Unveils Groundbreaking E. coli O157:H7 Detection Technology at Food Safety Meeting (IAFP*)
29 July, 2008
VIDAS® UP Recombinant Phage Technology Delivers Unprecedented Level
bioMérieux Unveils Extended Menu for the VIDAS UP Platform at the American Association for Clinical Chemistry's 2008 Annual Meeting
24 July, 2008
bioMérieux providing high medical-value tests such as Procalcitonin, Cardiovascular Critical Care Range and CDA+B.